Dallas Voice (Dallas, Tex.), Vol. 33, No. 32, Ed. 1 Friday, December 16, 2016 Page: 4 of 48
forty eight pages : ill.View a full description of this newspaper.
Extracted Text
The following text was automatically extracted from the image on this page using optical character recognition software:
©Tnunneq
abacavir6oo mg/dolutegravir 50 mg/
lamivudine 30omg tablets
IMPORTANT FACTS
This is only a brief summary of important information about TRIUMEQ and does not replace talking to
your healthcare provider about your condition and your treatment.
(TRI-u-meck)
MOST IMPORTANT INFORMATION ABOUT TRIUMEQ_
TRIUMEQ® may cause serious side effects, including:
• Serious allergic reactions (hypersensitivity reaction) that can cause death have
happened with TRIUMEQ and other abacavir-containing products. Your risk of this allergic
reaction to abacavir is much higher if you have a gene variation called HLA-B*5701. Your
healthcare provider can determine with a blood test if you have this gene variation. If you get
symptoms from 2 or more of the following groups while taking TRIUMEQ, call your
healthcare provider right away: 1. fever; 2. rash; 3. nausea, vomiting, diarrhea, or
stomach pain; 4. generally ill feeling, extreme tiredness, or achiness; 5. shortness
of breath, cough, or sore throat. A list of these symptoms is on the Warning Card your
pharmacist gives you. Carry this Warning Card with you at ail times.
• If you stop taking TRIUMEQ because of an allergic reaction, never take TRIUMEQ or
any other abacavir- or dolutegravir-containing medicines again. If you take TRIUMEQ
or any other abacavir-containing medicine again after you have had an allergic reaction,
within hours you may get life-threatening symptoms that may include very low blood
pressure or death. If you stop TRIUMEQ for any other reason, even for a few days, and you
are not allergic to TRIUMEQ, talk with your healthcare provider before taking it again. Taking
TRIUMEQ again can cause a serious allergic or life-threatening reaction, even if you never had
an allergic reaction to it before. If your healthcare provider tells you that you can take
TRIUMEQ again, start taking it when you are around medical help or people who
can call a healthcare provider if you need one.
• Build-up of lactic acid in your blood (lactic acidosis), which is a serious medical
emergency that can lead to death. Call your healthcare provider right away if you have
any of these symptoms: feeling very weak or tired, unusual muscle pain, trouble breathing,
stomach pain with nausea or vomiting, feeling cold (especially in your arms and legs), feeling
dizzy or lightheaded, and/or a fast or irregular heartbeat.
• Serious liver problems, which in some cases can lead to death. Call your healthcare
provider right away if you have any of these symptoms: your skin or the white part of
your eyes turns yellow (jaundice), dark “tea-colored” urine, light-colored stools (bowel
movements), loss of appetite for several days or longer, nausea, and/or stomach pain on the
right side.
You may be more likely to get lactic acidosis or severe liver problems if you are
female, very overweight, or have been taking nucleoside analogues for a long time.
• Worsening of Hepatitis B (HBV) infection. If you have both HIV-1 and HBV, your HBV may
suddenly get worse if you stop taking TRIUMEQ. Do not stop taking TRIUMEQ without first talking
to your healthcare provider, as they will need to check your health regularly for several months.
• Resistant HBV. If you have HIV-1 and HBV, the HBV can change (mutate) while you’re on
TRIUMEQ and become harder to treat (resistant).
• Use with interferon and ribavirin-based regimens. Worsening of liver disease that has
caused death has happened in people infected with both HIV-1 and hepatitis C virus who are
taking antiretroviral medicines and are also being treated for hepatitis C with interferon with
or without ribavirin. If you are taking TRIUMEQ and interferon with or without ribavirin, tell your
HCP if you have any new symptoms.
ABOUT TRIUMEQ_
• TRIUMEQ is a prescription HIV-1 medicine used alone or with other antiretroviral medicines to
treat HIV-1 infection in adults. TRIUMEQ is not for use by itself in people who have or have
had resistance to abacavir, dolutegravir, or lamivudine. TRIUMEQ should not be used in
children under the age of 18.
• TRIUMEQ does not cure HIV-1 infection or AIDS. You must keep taking HIV-1 medicines
to control HIV-1 infection and decrease HIV-related illnesses.
DO NOT TAKE TRIUMEQ IF YOU_
• have a certain type of gene variation called the HLA-B*5701 allele. Your HCP will test you for
this before prescribing treatment with TRIUMEQ.
• are allergic to abacavir, dolutegravir, or any of the ingredients in TRIUMEQ. See the full
Medication Guide for a complete list of ingredients in TRIUMEQ.
• take dofetilide (Tikosyn®). Taking TRIUMEQ and dofetilide (Tikosyn) can cause side effects
that may be life-threatening.
• have liver or kidney problems.
• If you also take: abacavir (EPZICOM, TRIZIVIR, or ZIAGEN); lamivudine (COMBIVIR®, Dutrebis™,
EPIVIR®, EPIVIR-HBV®, EPZICOM, or TRIZIVIR); emtricitabine (Atripla®, Complera®, Emtriva®,
Stribild®, or Truvada®) abacavir (EPZICOM, TRIZIVIR, or ZIAGEN)
BEFORE TAKING TRIUMEQ_
Tell your healthcare provider if you:
• have been tested and know if you have a particular gene variation called HLA-B*5701.
• have or had any kidney or liver problems, including hepatitis B or C virus infection.
• have heart problems, smoke, or have diseases that increase your risk of heart disease such
as high blood pressure, high cholesterol, or diabetes.
• drink alcohol or take medicines that contain alcohol.
• are pregnant or plan to become pregnant. It is not known if TRIUMEQ will harm your unborn baby.
• are breastfeeding (nursing) or plan to breastfeed. Do not breastfeed if you have HIV-1
because of the risk of passing HIV-1 to your baby.
Tell your healthcare provider about all the medicines you take:
• Keep a list that includes all prescription and over-the-counter medicines, vitamins, and herbal
supplements, and show it to your healthcare provider and pharmacist.
• Ask your healthcare provider or pharmacist about medicines that should not be
taken with TRIUMEQ. Do not start taking a new medicine without telling your
healthcare provider
MEDICINES THAT MIGHT INTERACT WITH TRIUMEQ_
• antacids, laxatives, or other medicines that contain aluminum, magnesium, sucralfate
(Carafate®), or buffered medicines. TRIUMEQ should be taken at least 2 hours before or
6 hours after you take these medicines.
• iron or calcium supplements taken by mouth may be taken at the same time with TRIUMEQ if
taken with food. Otherwise, TRIUMEQ should be taken at least 2 hours before or 6 hours after
you take these medicines
• anti-seizure medicines: oxcarbazepine (Trileptal®), phenytoin (Dilantin®, Dilantin®-125,
Phenytek®), phenobarbital, carbamazepine (Carbatrol®, Equetro®, Tegretol®, Tegretol®-XR,
Teril®, Epitol®)
• any other medicine to treat HIV-1, medicines used to treat hepatitis virus infections (such as
interferon or ribavirin), a medicine that contains metformin, methadone, rifampin (Rifater®
Rifamate® Rimactane®, Rifadin®), St. John's wort (Hypericum perforatum)
POSSIBLE SIDE EFFECTS OF TRIUMEQ_
TRIUMEQ can cause serious side effects including:
• See “What is the most important information about TRIUMEQ?” section
• Changes in liver tests.
• Changes in your immune system
• Changes in body fat
• Some HIV-1 medicines including TRIUMEQ may increase your risk of heart attack.
The most common side effects of TRIUMEQ are: trouble sleeping, headache, and tiredness
These are not all the possible side effects of TRIUMEQ. Tell your healthcare provider right away
if you have any new symptoms while taking TRIUMEQ.
Your healthcare provider will need to do tests to monitor your health before and
during treatment with TRIUMEQ.
You may report side effects to FDA at 1-800-FDA-1088.
GET MORE INFORMATION_
• Talk to your healthcare provider or pharmacist
• Go to TRIUMEQ.com or call 1 -877-844-8872, where you can also get FDA-approved product
labeling
COMBIVIR, EPIVIR, EPZICOM, TIVICAY, TRIUMEQ, TRIZIVIR, and ZIAGEN are registered
trademarks of the ViiV Healthcare group of companies.
EPIVIR-HBV is a registered trademark of the GSK group of companies.
The other brands listed are trademarks of their respective owners and are not trademarks of the
ViiV Healthcare group of companies. The makers of these brands are not affiliated with and do
not endorse the ViiV Healthcare group of companies or its products.
©2016, the ViiV Healthcare group of companies. All rights reserved.
April 2016 TRM:4MG
Upcoming Pages
Here’s what’s next.
Search Inside
This issue can be searched. Note: Results may vary based on the legibility of text within the document.
Tools / Downloads
Get a copy of this page or view the extracted text.
Citing and Sharing
Basic information for referencing this web page. We also provide extended guidance on usage rights, references, copying or embedding.
Reference the current page of this Newspaper.
Nash, Tammye. Dallas Voice (Dallas, Tex.), Vol. 33, No. 32, Ed. 1 Friday, December 16, 2016, newspaper, December 16, 2016; Dallas, Texas. (https://texashistory.unt.edu/ark:/67531/metapth1007223/m1/4/: accessed July 12, 2024), University of North Texas Libraries, The Portal to Texas History, https://texashistory.unt.edu.; crediting UNT Libraries Special Collections.